What is William Blair’s Forecast for IPSC Q3 Earnings?

Century Therapeutics, Inc. (NASDAQ:IPSC) – Analysts at William Blair issued their Q3 2026 earnings per share estimates for Century Therapeutics in a report issued on Thursday, March 20th. William Blair analyst S. Corwin forecasts that the company will post earnings of ($0.47) per share for the quarter. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.61) per share.

Several other research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Piper Sandler cut their price target on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Guggenheim decreased their price objective on Century Therapeutics from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $5.80.

Century Therapeutics Price Performance

Shares of NASDAQ IPSC opened at $0.56 on Friday. The firm’s 50-day moving average is $0.74 and its two-hundred day moving average is $1.16. The company has a market capitalization of $47.19 million, a PE ratio of -0.30 and a beta of 1.75. Century Therapeutics has a 12-month low of $0.52 and a 12-month high of $4.50.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.02. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The business had revenue of $4.18 million for the quarter, compared to analyst estimates of $0.67 million.

Hedge Funds Weigh In On Century Therapeutics

Several institutional investors have recently added to or reduced their stakes in IPSC. Geode Capital Management LLC grew its holdings in Century Therapeutics by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock valued at $1,656,000 after buying an additional 32,614 shares during the period. Barclays PLC boosted its position in shares of Century Therapeutics by 283.6% in the third quarter. Barclays PLC now owns 61,945 shares of the company’s stock worth $106,000 after acquiring an additional 45,797 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Century Therapeutics by 257.6% in the third quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock valued at $123,000 after purchasing an additional 51,664 shares during the period. State Street Corp increased its position in Century Therapeutics by 7.4% during the third quarter. State Street Corp now owns 836,914 shares of the company’s stock worth $1,431,000 after purchasing an additional 57,323 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Century Therapeutics during the third quarter worth approximately $284,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.